These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 13679853

  • 21. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M, Cerni C, Lüscher-Firzlaff JM, Lüscher B.
    Oncogene; 1998 Jul 30; 17(4):511-20. PubMed ID: 9696045
    [Abstract] [Full Text] [Related]

  • 22. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W, Schneider ML, Matt T, Kräutler B, Konrat R, Bister K.
    J Mol Biol; 2001 Apr 13; 307(5):1395-410. PubMed ID: 11292350
    [Abstract] [Full Text] [Related]

  • 23. Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc.
    FitzGerald MJ, Arsura M, Bellas RE, Yang W, Wu M, Chin L, Mann KK, DePinho RA, Sonenshein GE.
    Oncogene; 1999 Apr 15; 18(15):2489-98. PubMed ID: 10229200
    [Abstract] [Full Text] [Related]

  • 24. DNA binding of Myc/Max/Mad network complexes to oligonucleotides containing two E box elements: c-Myc/Max heterodimers do not bind DNA cooperatively.
    Vervoorts J, Lüscher B.
    Biol Chem; 1999 Sep 15; 380(9):1121-6. PubMed ID: 10543451
    [Abstract] [Full Text] [Related]

  • 25. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S, Blomhoff HK.
    J Cell Physiol; 1999 Jan 15; 178(1):76-84. PubMed ID: 9886493
    [Abstract] [Full Text] [Related]

  • 26. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
    Västrik I, Mäkelä TP, Koskinen PJ, Saksela K, Alitalo K.
    Princess Takamatsu Symp; 1991 Jan 15; 22():307-18. PubMed ID: 1668890
    [Abstract] [Full Text] [Related]

  • 27. Functions of myc:max in the control of cell proliferation and tumorigenesis.
    Hurlin PJ, Dezfouli S.
    Int Rev Cytol; 2004 Jan 15; 238():183-226. PubMed ID: 15364199
    [Abstract] [Full Text] [Related]

  • 28. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K, Henriksson M, Lüscher-Firzlaff JM, Litchfield DW, Lüscher B.
    Oncogene; 1993 Dec 15; 8(12):3211-20. PubMed ID: 8247525
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
    Larsson LG, Bahram F, Burkhardt H, Lüscher B.
    Oncogene; 1997 Aug 07; 15(6):737-48. PubMed ID: 9264414
    [Abstract] [Full Text] [Related]

  • 33. DNA binding by N- and L-Myc proteins.
    Ma A, Moroy T, Collum R, Weintraub H, Alt FW, Blackwell TK.
    Oncogene; 1993 Apr 07; 8(4):1093-8. PubMed ID: 8455937
    [Abstract] [Full Text] [Related]

  • 34. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C, Chen N, Sawadogo M.
    Exp Cell Res; 2005 Jan 01; 302(1):1-10. PubMed ID: 15541720
    [Abstract] [Full Text] [Related]

  • 35. Max and c-Myc/Max DNA-binding activities in cell extracts.
    Littlewood TD, Amati B, Land H, Evan GI.
    Oncogene; 1992 Sep 01; 7(9):1783-92. PubMed ID: 1501888
    [Abstract] [Full Text] [Related]

  • 36. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells.
    Delgado MD, Lerga A, Cañelles M, Gómez-Casares MT, León J.
    Oncogene; 1995 Apr 20; 10(8):1659-65. PubMed ID: 7731722
    [Abstract] [Full Text] [Related]

  • 37. Taking myc to the max.
    Turner R.
    Nat Struct Biol; 2003 Mar 20; 10(3):157. PubMed ID: 12605219
    [No Abstract] [Full Text] [Related]

  • 38. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancuso T, Bagnasco L, Russo P, Parodi S.
    Cancer Res; 1998 Aug 15; 58(16):3654-9. PubMed ID: 9721875
    [Abstract] [Full Text] [Related]

  • 39. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
    Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA.
    Oncogene; 1996 Mar 07; 12(5):1165-72. PubMed ID: 8649810
    [Abstract] [Full Text] [Related]

  • 40. c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs.
    Tobias KE, Shor J, Kahana C.
    Oncogene; 1995 Nov 02; 11(9):1721-7. PubMed ID: 7478599
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.